In the light of the potential synergism between IGF1R inhibitors (IGF1Ri) and conventional chemotherapy, the addition of ganitumab to chemotherapy in newly diagnosed metastatic ES patients was investigated in a phase III trial [21]. The gene discussed is IGF1R; the disease is epithelioid sarcoma.